Effects of rituximab in two patients with dysferlin-deficient muscular dystrophy (Q30985481)

12 October 2017

Effects of rituximab in two patients with dysferlin-deficient muscular dystrophy (English)

1 reference

12 October 2017

1 reference

1 reference

Laura Porretti

0 references

Yvan Torrente

0 references

Nereo Bresolin

0 references

Alberto Lerario

1 reference

12 October 2017

Filippo Cogiamanian

series ordinal

1 reference

12 October 2017

Chiara Marchesi

series ordinal

1 reference

12 October 2017

Marzia Belicchi

series ordinal

1 reference

12 October 2017

11 July 2010

1 reference

BMC Musculoskeletal Disorders

12 October 2017

1 reference

12 October 2017

1 reference

12 October 2017

157

1 reference

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

12 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2912795

Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2912795

Human circulating AC133(+) stem cells restore dystrophin expression and ameliorate function in dystrophic skeletal muscle

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2912795

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2912795

Rituximab therapy for multisystem autoimmune diseases in pediatric patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2912795

B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2912795

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2912795

B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2912795

Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2912795

Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2912795

Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2912795

Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2912795

Dysferlin mutations in Japanese Miyoshi myopathy: relationship to phenotype

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2474-11-157

Increased susceptibility to complement attack due to down-regulation of decay-accelerating factor/CD55 in dysferlin-deficient muscular dystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2474-11-157

Improved isometric force endurance after transcranial direct current stimulation over the human motor cortical areas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2474-11-157

Treatment of IgM antibody associated polyneuropathies using rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2474-11-157

A novel compound heterozygous dysferlin mutation in Miyoshi myopathy siblings responding to dantrolene

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2474-11-157

Rituximab as therapy for refractory polymyositis and dermatomyositis.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2912795

Muscle pathology in dysferlin deficiency

25 November 2018

1 reference

12 December 2020

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab

1 reference

12 December 2020

Quantitation of muscle function in children: a prospective study in Duchenne muscular dystrophy

1 reference

12 December 2020

Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation

1 reference

12 December 2020

The B cell surface molecule B1 is functionally linked with B cell activation and differentiation

1 reference

12 December 2020

1 reference

12 December 2020

Rituximab in the treatment of dermatomyositis: an open-label pilot study

1 reference

12 December 2020

1 reference

12 December 2020

Rituximab in indolent lymphoma: the single-agent pivotal trial

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2474-11-157

1 reference

Dimensions Publication ID

12 October 2017

0 references

1 reference

12 October 2017

PubMed publication ID

20618995

1 reference